Humoral rejection is refractory to conventional high-dose corticosteroid pulse therapy and invariably requires the addition of depleting antibodies, either polyclonal antilymphocyte agents or OKT3.

There has been a great deal of recent work that has used the combination of plasmapheresis and intravenous immunoglobulin (IVIG) to treat humoral rejection. It seems to be an important advance.

In a phase 2 trial, felzartamab showed acceptable safety and potential therapeutic benefits in kidney transplant recipients with antibody-mediated rejection. Felzartamab shows acceptable safety and ...